CombinatoRx, a combination drugs developer, and Neuromed, which develops pain therapies, have agreed to merge in an all stock transaction with each party owning approximately 50%. The new company will retain the CombinatoRx name and the relative ownership will be adjusted based upon the outcome of the FDA’s review of Neuromed’s Exalgo™ (hydromorphone HCl), which is expected to be in late 2009.